|
70
|
243
|
4qvqF |
Ycp beta5-m45i mutant in complex with bortezomib |
|
66
|
250
|
4qw1A |
Ycp beta5-a50v mutant in complex with bortezomib |
|
67
|
250
|
4qz1A |
Ycp beta5-m45t mutant in complex with the epoxyketone inhibitor onx 0914 |
|
63
|
195
|
4qvpJ |
Ycp beta5-m45t mutant in complex with bortezomib |
|
62
|
238
|
4r67F |
Human constitutive 20s proteasome in complex with carfilzomib |
|
59
|
226
|
4qw1H |
Ycp beta5-a50v mutant in complex with bortezomib |
|
67
|
233
|
4qv7M |
Ycp beta5-a50v mutant |
|
70
|
212
|
4qz7K |
Ycp beta5-a50v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
62
|
222
|
4qlsH |
Ycp in complex with tripeptidic epoxyketone inhibitor 11 |
|
64
|
231
|
4qzzE |
Ycp in complex with omuralide |
|
65
|
231
|
4r18E |
Ligand-induced lys33-thr1 crosslinking at subunit beta5 of the yeast 20s proteasome |
|
72
|
212
|
4qz0K |
Ycp beta5-m45v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
66
|
244
|
4qwiB |
Ycp beta5-a49s-mutant in complex with carfilzomib |
|
66
|
244
|
4r67A |
Human constitutive 20s proteasome in complex with carfilzomib |
|
62
|
231
|
4qz5E |
Ycp beta5-a49t-mutant in complex with onx 0914 |
|
71
|
243
|
4qwjF |
Ycp beta5-a49t-mutant in complex with carfilzomib |
|
68
|
242
|
4qz6D |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
|
56
|
204
|
4qwxI |
Ycp in complex with the epoxyketone inhibitor onx 0914 |
|
67
|
250
|
4qv7A |
Ycp beta5-a50v mutant |
|
65
|
231
|
4qzwE |
Ycp beta5-c52f mutant in complex with the epoxyketone inhibitor onx 0914 |
|
67
|
212
|
4qv8K |
Ycp beta5-c52f mutant |
|
58
|
222
|
4qw6H |
Ycp beta5-m45v mutant in complex with carfilzomib |
|
68
|
212
|
4quxK |
Ycp beta5-a49t-mutant |
|
67
|
212
|
4r00K |
Ycp beta5-c52f mutant in complex with omuralide |
|
56
|
204
|
4qvyI |
Ycp beta5-a49t-mutant in complex with bortezomib |
|
57
|
204
|
4quxI |
Ycp beta5-a49t-mutant |
|
56
|
202
|
4r67H |
Human constitutive 20s proteasome in complex with carfilzomib |
|
62
|
231
|
4qw1E |
Ycp beta5-a50v mutant in complex with bortezomib |
|
69
|
233
|
4qv9M |
Ycp beta5-c63f mutant |
|
66
|
242
|
4qz7D |
Ycp beta5-a50v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
66
|
242
|
4qltD |
Ycp in complex with tripeptidic epoxyketone inhibitor 2 (pr924) |
|
67
|
250
|
4qxjA |
Ycp beta5-m45a mutant in complex with the epoxyketone inhibitor onx 0914 |
|
59
|
222
|
4qw3L |
Ycp beta5-c63f mutant in complex with bortezomib |
|
59
|
226
|
4qvlH |
Ycp in complex with bortezomib |
|
68
|
212
|
4qlvK |
Ycp in complex with tripeptidic epoxyketone inhibitor 17 |
|
60
|
196
|
4qzwN |
Ycp beta5-c52f mutant in complex with the epoxyketone inhibitor onx 0914 |
|
72
|
212
|
4qwjK |
Ycp beta5-a49t-mutant in complex with carfilzomib |
|
70
|
243
|
4qvvF |
Ycp beta5-a49v mutant in complex with bortezomib |
|
70
|
212
|
4r02K |
Ycp in complex with bsc4999 (alpha-keto phenylamide) |
|
62
|
241
|
4qz3G |
Ycp beta5-a49v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
61
|
195
|
4qw6J |
Ycp beta5-m45v mutant in complex with carfilzomib |
|
64
|
231
|
4qw5E |
Ycp beta5-m45a mutant in complex with carfilzomib |
|
58
|
222
|
4qw1L |
Ycp beta5-a50v mutant in complex with bortezomib |
|
64
|
231
|
4qz7E |
Ycp beta5-a50v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
66
|
242
|
4qxjD |
Ycp beta5-m45a mutant in complex with the epoxyketone inhibitor onx 0914 |
|
71
|
243
|
4qw5F |
Ycp beta5-m45a mutant in complex with carfilzomib |
|
68
|
242
|
4qvnD |
Ycp beta5-m45v mutant in complex with bortezomib |
|
71
|
240
|
4r00C |
Ycp beta5-c52f mutant in complex with omuralide |
|
65
|
244
|
4qwgB |
Ycp beta5-a49v mutant in complex with carfilzomib |
|
59
|
222
|
4qluH |
Ycp in complex with tripeptidic epoxyketone inhibitor 9 |
